Description
An inhibitor of VEGFR2; inhibits VEGFR2 activity by 97% but also inhibits FGFR2 and PDGFRβ activity by 65 and 55%, respectively, at 10 µM; selective for VEGFR2, FGFR2, and PDGFRβ over PI3K, EGFR, Aurora A, Cdk2/cyclin E, and Cdk6/cyclin D3 at 10 µM; inhibits VEGF- and bFGF-induced proliferation of HUVECs (IC50s = 2.2 and 4.7 µM, respectively); inhibits HUVEC capillary tube formation and migration at 2.5 and 10 µM, respectively; inhibits proliferation of a variety of cancer cells, including A549, HCT116, MDA-MB-231, Raji and DU145 cells (IC50s = 5.7, 5.3, 25.6, 6.4, and 6.3 µM, respectively); reduces tumor growth in A549 and HCT116 mouse xenograft models at 50 mg/kg per day
Formal name: N-methyl-4-[4-[[3-(trifluoromethyl)benzoyl]amino]phenoxy]-2-pyridinecarboxamide
Synonyms:
Molecular weight: 415.4
CAS: 1125780-41-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling